KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $88,730.62 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 3,322 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $26.71, for a total value of $88,730.62. Following the completion of the sale, the chief executive officer owned 466,375 shares of the company’s stock, valued at $12,456,876.25. The trade was a 0.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $26.73 on Friday. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -6.77 and a beta of -0.12. The stock has a fifty day simple moving average of $20.40 and a 200 day simple moving average of $16.72. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $26.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Friday, May 15th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $39.17 million during the quarter, compared to the consensus estimate of $39.14 million. Sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wall Street Zen downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Stifel Nicolaus increased their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Leerink Partners downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. JonesTrading downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Citizens Jmp downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $30.60.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently made changes to their positions in KALV. Parallel Advisors LLC grew its stake in shares of KalVista Pharmaceuticals by 45.8% in the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 589 shares during the period. BNP Paribas Financial Markets grew its stake in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $55,000. Wolverine Asset Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $57,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $63,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.